Stockscreener 앱 받기
9.68
0.52%
0.05
전일 마감가:
$9.63
열려 있는:
$9.54
하루 거래량:
240.02K
Relative Volume:
0.30
시가총액:
$517.03M
수익:
$8.78M
순이익/손실:
$-104.70M
주가수익비율:
-4.0844
EPS:
-2.37
순현금흐름:
$-82.68M
1주 성능:
+2.22%
1개월 성능:
+62.96%
6개월 성능:
-25.82%
1년 성능:
-19.47%
1일 변동 폭
$9.41
$9.74
1주일 범위
$9.13
$10.12
52주 변동 폭
$5.35
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
STOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
9.68 | 517.03M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.89 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.86 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.45 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.26 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.84 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
JPMorgan Chase & Co. Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Monday - Defense World
Technical analysis of Stoke Therapeutics Inc (STOK) stock chart patterns - uspostnews.com
Biogen tops estimates on rare disease strength, cuts full-year guidance - The Pharma Letter
Legal & General Group Plc Decreases Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Market Momentum Report: Stoke Therapeutics Inc (STOK)’s Negative Close at 9.47 - DWinneX
Renaissance Technologies LLC Invests $1.42 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Market Highlights: Stoke Therapeutics Inc (STOK) Ends on a High Note at 9.52 - DWinneX
Stoke Therapeutics Inc (STOK) deserves deeper analysis - uspostnews.com
Geode Capital Management LLC Purchases 6,264 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? - MSN
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Stoke Therapeutics Inc (STOK) rating initates by Chardan Capital Markets - knoxdaily.com
(STOK) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Leerink Partnrs Issues Optimistic Estimate for STOK Earnings - Defense World
Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be - simplywall.st
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of “Buy” by Analysts - Defense World
Vanguard Group Inc. Sells 28,049 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Wellington Management Group LLP Has $1.49 Million Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Needham & Company LLC Reiterates Buy Rating for Stoke Therapeutics (NASDAQ:STOK) - Defense World
Needham Keeps Their Buy Rating on Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - simplywall.st
Stoke Therapeutics stock hits 52-week low at $6.09 amid market challenges By Investing.com - Investing.com South Africa
Stoke Therapeutics stock hits 52-week low at $6.09 amid market challenges - Investing.com India
Teacher Retirement System of Texas Purchases Shares of 10,219 Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire
Revolutionary RNA Treatment for Rare Disease: Stoke CEO to Reveal Latest Progress - Stock Titan
Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential - TradingView
Swiss National Bank Acquires 11,400 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
FY2025 Earnings Forecast for STOK Issued By Chardan Capital - Defense World
Charles Schwab Investment Management Inc. Grows Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges By Investing.com - Investing.com South Africa
Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges - Investing.com Australia
Dravet Syndrome Market Expected to Experience Major Growth - openPR.com
Bank of New York Mellon Corp Acquires 1,330 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
(STOK) Technical Data - news.stocktradersdaily.com
Cantor Fitzgerald Issues Positive Forecast for STOK Earnings - Defense World
Wedbush Equities Analysts Raise Earnings Estimates for STOK - Armenian Reporter
Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Brokers Offer Predictions for STOK Q3 Earnings - Defense World
What is Leerink Partnrs’ Forecast for STOK Q1 Earnings? - Defense World
Q1 EPS Estimates for Stoke Therapeutics Increased by Wedbush - Defense World
Stoke Therapeutics general counsel sells shares totaling $35,731 By Investing.com - Investing.com South Africa
Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Chardan Capital - Defense World
Analysts Issue Forecasts for STOK Q1 Earnings - Defense World
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
0.30%
자본화:
|
볼륨(24시간):